The Board of Directors of Zydus Lifesciences Limited convened a meeting on May 19, 2026, to deliberate upon key leadership changes. Based on the recommendations of the Nomination and Remuneration Committee, the board approved significant appointments aimed at strengthening the company's governance structure.

Re-appointment of Managing Director

The board approved the re-appointment of Dr. Sharvil P. Patel as the Managing Director of the company. His tenure is set for a further period of five years, commencing on April 1, 2027, and concluding on March 31, 2032. This extension is contingent upon receiving shareholder approval via a special resolution at the upcoming Annual General Meeting. Dr. Patel is the son of Mr. Pankaj R. Patel, the Chairman of the company.

Appointment of Independent Director

In a separate decision, the board appointed Mr. Kulin S. Lalbhai as an Additional Director and Independent Director. His appointment is effective immediately from May 19, 2026, for a term of five years. This role is also subject to shareholder approval through a special resolution at the ensuing Annual General Meeting. Mr. Lalbhai is not liable to retire by rotation.

Director Profiles

Dr. Sharvil Patel brings extensive experience in the pharmaceutical and research sectors. He currently serves as the Managing Director and holds a doctorate from the University of Sunderland, U.K. He is also the Chairman of Zydus Wellness Limited. Mr. Kulin S. Lalbhai holds an MBA from Harvard Business School and a B. Sc. in Electrical Engineering from Stanford University. He currently serves as the Whole Time Director of Arvind Limited, leading its consumer-facing and digital businesses.

The following table summarizes the key details of the board appointments:

Zydus Lifesciences Limited has announced Friday, July 24, 2026, as the record date to determine the eligibility of shareholders entitled to receive the final dividend for the financial year ended March 31, 2026. The record date is in compliance with Regulation 42(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's Board, which met on May 19, 2026, had recommended a final dividend of 100%, or Re. 1/- per equity share of Re. 1/- each, subject to the approval of shareholders at the upcoming Annual General Meeting (AGM).

The company has scheduled its Thirty First Annual General Meeting for Tuesday, August 11, 2026, to be held through Video Conference or Other Audio Visual Means. The payment of the dividend, subject to deduction of tax at source, is expected to be made on or around Friday, August 14, 2026, pending shareholder approval at the AGM.

Consolidated Financial Performance

For the financial year 2025-26, Zydus Lifesciences reported total revenue from operations of INR 271,484 million, an increase of 16.8% from INR 232,415 million in the previous year. Consolidated net profit for the year stood at INR 50,400 million, while adjusted net profit rose 15% to INR 54,564 million. For the quarter ended March 31, 2026, revenue from operations was INR 75,870 million, and net profit was INR 12,725 million.

Standalone Financial Performance

On a standalone basis, the company reported total revenue from operations of INR 114,840 million for FY26, compared to INR 151,163 million in the prior year. Net profit for the year stood at INR 35,598 million, against INR 57,749 million in the previous year. The quarter ended March 31, 2026, recorded standalone revenue from operations of INR 37,409 million and net profit of INR 17,220 million.